MedTrace Logo

Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

NCT07486869 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-04-09

No results posted yet for this study

Summary

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.

Conditions

  • Dermatomyositis
  • Dermatomyositis Sine Myositis
  • Dermatomyositis With Myopathy
  • Dermatomyositis With Respiratory Involvement
  • Dermatomyositis With Organ Involvement
  • Interstitial Lung Disease
  • Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)

Interventions

DRUG

Emapalumab

Emapalumab administered intravenously according to the following dosing regimen: 6 mg/kg on Day 1, followed by 3 mg/kg every 3 days for 2 weeks, and then 3 mg/kg twice weekly for 2 weeks.

Sponsors & Collaborators

  • Swedish Orphan Biovitrum AB

    collaborator UNKNOWN

  • University of Miami

    lead OTHER

Principal Investigators

  • Kelly Corbitt, D.O. · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07486869 on ClinicalTrials.gov